[
  {
    "ts": "2025-12-02T06:00:00+00:00",
    "headline": "Pre-filled Syringe Presentation of BYOOVIZ®, Samsung Bioepis' Biosimilar to Lucentis (Ranibizumab), Gains European Approval",
    "summary": "INCHEON, Korea, December 02, 2025--Samsung Bioepis' Byooviz PFS gains European approval.",
    "url": "https://finance.yahoo.com/news/pre-filled-syringe-presentation-byooviz-060000496.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "bfacf0f9-30bb-3138-b3b7-87b2331ccea2",
      "content": {
        "id": "bfacf0f9-30bb-3138-b3b7-87b2331ccea2",
        "contentType": "STORY",
        "title": "Pre-filled Syringe Presentation of BYOOVIZ®, Samsung Bioepis' Biosimilar to Lucentis (Ranibizumab), Gains European Approval",
        "description": "",
        "summary": "INCHEON, Korea, December 02, 2025--Samsung Bioepis' Byooviz PFS gains European approval.",
        "pubDate": "2025-12-02T06:00:00Z",
        "displayTime": "2025-12-02T06:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/c728fb2bd8c3bdcc41440a298fd56af9",
          "originalWidth": 1270,
          "originalHeight": 458,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qklwyMCi.L1RskpQu4G.NQ--~B/aD00NTg7dz0xMjcwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/c728fb2bd8c3bdcc41440a298fd56af9.cf.webp",
              "width": 1270,
              "height": 458,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/I5hhrXzEtWRmQdNOOl58Iw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/c728fb2bd8c3bdcc41440a298fd56af9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pre-filled-syringe-presentation-byooviz-060000496.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pre-filled-syringe-presentation-byooviz-060000496.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-02T22:11:22+00:00",
    "headline": "Biogen (BIIB): Assessing Valuation After Recent Share Price Gains",
    "summary": "Biogen (BIIB) shares have been actively discussed lately, as some investors weigh the stock's longer-term track record against recent performance. Over the past month, Biogen stock has climbed by 15%, which is higher compared to its returns from earlier periods. See our latest analysis for Biogen. Momentum has picked up for Biogen lately, with a 15% one-month share price return and year-to-date gains of 18%, signaling renewed optimism after a tough few years. Still, its 1-year total...",
    "url": "https://finance.yahoo.com/news/biogen-biib-assessing-valuation-recent-221122944.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "1006413b-10ff-3a84-959f-7a1ed4b2ddf3",
      "content": {
        "id": "1006413b-10ff-3a84-959f-7a1ed4b2ddf3",
        "contentType": "STORY",
        "title": "Biogen (BIIB): Assessing Valuation After Recent Share Price Gains",
        "description": "",
        "summary": "Biogen (BIIB) shares have been actively discussed lately, as some investors weigh the stock's longer-term track record against recent performance. Over the past month, Biogen stock has climbed by 15%, which is higher compared to its returns from earlier periods. See our latest analysis for Biogen. Momentum has picked up for Biogen lately, with a 15% one-month share price return and year-to-date gains of 18%, signaling renewed optimism after a tough few years. Still, its 1-year total...",
        "pubDate": "2025-12-02T22:11:22Z",
        "displayTime": "2025-12-02T22:11:22Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/I2k3PKJsWIEX9xgEQz8JwQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tmSjpFKmBAT61w1lG5.BLQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/biogen-biib-assessing-valuation-recent-221122944.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/biogen-biib-assessing-valuation-recent-221122944.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-02T21:40:00+00:00",
    "headline": "New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF",
    "summary": "Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \"Eisai\") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, \"Biogen\") announced today that the latest data confirming the pharmacological effect of lecanemab (generic name, U.S. brand name: LEQEMBI®), an anti-Aβ protofibril* antibody, on Aβ protofibrils (PF) in cerebrospinal fluid (CSF) was presented at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference. The findin",
    "url": "https://finance.yahoo.com/news/data-presented-clinical-trials-alzheimers-214000041.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "64d1e95e-d337-3019-8c19-8cca5cde98eb",
      "content": {
        "id": "64d1e95e-d337-3019-8c19-8cca5cde98eb",
        "contentType": "STORY",
        "title": "New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF",
        "description": "",
        "summary": "Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \"Eisai\") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, \"Biogen\") announced today that the latest data confirming the pharmacological effect of lecanemab (generic name, U.S. brand name: LEQEMBI®), an anti-Aβ protofibril* antibody, on Aβ protofibrils (PF) in cerebrospinal fluid (CSF) was presented at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference. The findin",
        "pubDate": "2025-12-02T21:40:00Z",
        "displayTime": "2025-12-02T21:40:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/8fbe328e0f2d5337d2839c8345101b15",
          "originalWidth": 400,
          "originalHeight": 112,
          "caption": "Eisai logo and Biogen logo (PRNewsfoto/Eisai Co., Ltd.)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bJrlns2nzwpK84mfnZzsTg--~B/aD0xMTI7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/8fbe328e0f2d5337d2839c8345101b15.cf.webp",
              "width": 400,
              "height": 112,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lpiHqXXYlwJmL4_lRc2Yvw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/8fbe328e0f2d5337d2839c8345101b15.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/data-presented-clinical-trials-alzheimers-214000041.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/data-presented-clinical-trials-alzheimers-214000041.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "ESAIY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-02T21:40:00+00:00",
    "headline": "New Data Presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF",
    "summary": "TOKYO and CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the latest data confirming the pharmacological effect of lecanemab (generic name, U.S. brand name: LEQEMBI®), an anti-Aβ protofibril* antibody, on Aβ protofibrils (PF) in cerebrospinal fluid (CSF) was presented at the 18th Clinic",
    "url": "https://finance.yahoo.com/news/data-presented-clinical-trials-alzheimer-214000833.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "71b67c1a-98a3-3a9b-84f6-f12a8424050b",
      "content": {
        "id": "71b67c1a-98a3-3a9b-84f6-f12a8424050b",
        "contentType": "STORY",
        "title": "New Data Presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF",
        "description": "",
        "summary": "TOKYO and CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the latest data confirming the pharmacological effect of lecanemab (generic name, U.S. brand name: LEQEMBI®), an anti-Aβ protofibril* antibody, on Aβ protofibrils (PF) in cerebrospinal fluid (CSF) was presented at the 18th Clinic",
        "pubDate": "2025-12-02T21:40:00Z",
        "displayTime": "2025-12-02T21:40:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d",
          "originalWidth": 865,
          "originalHeight": 290,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IDD9DHtEaM8wc.4J0e2kkA--~B/aD0yOTA7dz04NjU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d.cf.webp",
              "width": 865,
              "height": 290,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iODOrgJZ_MV95T9B.jt0vw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/data-presented-clinical-trials-alzheimer-214000833.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/data-presented-clinical-trials-alzheimer-214000833.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "ESAIY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]